UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K/A

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2020

Commission File Number: 001-39461

NANO-X IMAGING LTD

Communications Center
Neve Ilan, Israel 9085000
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

EXPLANATORY NOTE

NANO-X IMAGING LTD is furnishing this Form 6-K/A in order to re-file and replace Exhibit 99.1 to the Form 6-K of NANO-X IMAGING LTD furnished to the Securities and Exchange Commission on September 22, 2020 (the "Original Form 6-K"). This Form 6-K/A is being furnished solely to correct a typographical error in the number of contracted Nanox.ARC systems in Exhibit 99.1 to the Original Form 6-K, and state that the number of contracted Nanox.ARC systems is 5,150. All other information included in the Original Form 6-K remains unchanged. The corrected Exhibit 99.1 is submitted with this Form 6-K/A as Exhibit 99.1.

EXHIBIT INDEX

Exhibit No.	Exhibit
99.1	NANO-X IMAGING LTD's presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANO-X IMAGING, INC.

By: /s/ Tal Shank
Name: Tal Shank
Title: Vice President of Corporate Development

Date: September 22, 2020

Exhibit 99.1


NANOX
Dawn of early detection healthcare
Investor Presentation
September 2020

Disclaimers

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all inclusive or to contain all of the information about the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Information Statement

Statements contained in this presentation concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact are “forward-looking statements.” These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “target,” “project,” “forecast,” “seek,” “will,” “may,” “should,” “could,” “would” or similar expressions. Although Nanox believes that the expectations and assumptions reflected in these statements are reasonable, these expectations or forecasts of future performance may not prove to be correct. Forward-looking statements are subject to many risks and uncertainties, and actual results may differ materially from the results discussed in forward-looking statements. The following are among the important factors that could cause actual results to differ materially from the forward-looking statements: risks related to Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-Ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; the market acceptance of the Nanox.ARC and the proposed pay-per-scan business model; Nanox’s expectations regarding collaborations with third-parties and their potential benefits; Nanox’s ability to conduct business globally; the impact of general economic conditions, general conditions in the medical technology and imaging industries; the impact of the COVID-19 pandemic on the Company's business operations; changes in the global and regional regulatory environments in the jurisdictions in which Nanox does or plans to do business; and market volatility, fluctuations in costs and changes to the competitive environment, among others. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Other risks and uncertainties of which Nanox is not currently aware may also affect these forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and Nanox is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

These risks and uncertainties are described more fully under the caption ”Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Other risks and uncertainties of which the Company is not currently aware may also affect Company’s forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Market and Industry Data and Customer Information

This presentation has been prepared by Nanox and includes market data and other information from sources believed by us to be reliable. For example, industry and market data, including our own research, and surveys or industry publications and surveys as well as public information about our customers and discussion with them. Some data are also based on our good-faith estimates, which are derived from Nanox’s review of internal sources as well as the other sources described above. Although Nanox believes these sources are reliable, Nanox has not independently verified the information is accurate and complete. As a result, you should be aware that market share, ranking and other similar data set forth in this presentation, and estimates and beliefs based on such data may not be reliable.

NANOX

Nanox in a glance

The What

Nanox aims to build a global infrastructure for medical imaging

Utilizing innovative, patent protected and disruptive technology, Nanox can offer medical technology that expands access, resulting in better outcomes and lower costs.

Until today, technology was the barrier to medical imaging availability.

Nanox believes it has broken that barrier.

With global execution starting this year Nanox invites partners to join the potentially next revolution in preventive healthcare.

Unmet need

Massive deficit of medical imaging systems due to high system costs

2/3 of the world population has no access to medical imaging.

Weeks and months of wait times for radiology diagnostics results.

Game changing tech

A novel digital X-Ray source replacing an analog X-Ray that has been used for over 100 years enables significant cost reduction

A new breed of medical imaging infrastructure that can be deployed in mass due to significantly lower costs and small footprint coupled with a radiology services cloud platform

Upcoming Milestones

We are targeting several near term value catalysts such as FDA approval and commercialization



Disruptive business model

Executed contracts for 5,150 units pending regulatory approvals

Medical Screening as a Service (MSaaS) opens a recurring revenue model that has the potential to provide substantial revenues

Planning global mass deployment of 15,000 systems with a Pay-per-Scan subscription model

See slide 25 for full detail and assumptions

ILLUSTRATIVE MODEL

POTENTIAL ANNUSL RECURRING REVENUE ASSUMING THE 5,150 CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL





Strategic Shareholders FUJI FOXCONN SK telecom

Exceptionally seasoned execution team

Healthcare and technology veterans from companies like GE, Philips, and highly successful, game-changing technology entrepreneurs

Preventive screening

Early detection is key to preventive healthcare.

Treatable conditions, such as cancer, cardiovascular failures and others are often diagnosed too late.



Early detection remains theoretical

2/3 of the world's population have no access to medical imaging

The majority of the remaining 1/3 suffer from weeks and months of wait time for access to medical scanners and diagnostic results.

Why?

Medical imaging systems are too expensive and complex for mass deployment.



The key inhibitor

X-Ray source technology has not changed since its discovery over 120 years ago

Wilhelm Conrad Röntgen

The hot cathode



Modern day X-Ray tube
Analog X-Ray source

Heats up a metal filament to **2,000° Celsius** to produce the electron streams necessary for X-Ray emission

NANOX

Main contributor to high-cost of imaging systems

The legacy analog X-Ray source

Requires extremely high-voltage, complex mechanics and special cooling to produce the electrons needed for X-Ray emission, resulting in an average $150,000 cost for the source alone



NANOX

The Nanox paradigm



A fundamental technological change in the X-Ray source

Will result in lower cost and smaller imaging systems

Which we expect will enable significantly higher availability of imaging services

Driving higher rates of medical prevention through early-detection.

NANOX

Introducing the novel Nanox X-Ray source

Novel silicon-based, low voltage, nano-scale cold cathode

Generating the electrons streams needed for X-Ray via cold field-emission technology



X-Ray Reimagined

NANOX

Nanox MEMs X-Ray source

- Technology originally developed by Sony and its partners to achieve a higher quality image for screens and monitors
- Sony invested substantial resources in the development of this technology for over a decade
- After acquiring the technology, our Japanese-Israeli team invested over 8 years developing a source for the medical imaging industry based on this technology
- Nanox-owned manufacturing facilities in Japan
- Signed agreement with SK Telecom for collaboration on a new Korean factory to increase Nanox MEMs production capacity
- Mature and optimized proprietary technology and production process with an exceptionally high-yield
- Strong IP portfolio with patents granted in USA, Israel, Japan and pending globally

NANOX CLEAN ROOM (JAPAN)



NANOX WAFER



Tech transformation

From



One metal filament heated to 2,000° Celsius requiring special cooling and rotation mechanics

To



100 Million nano-cones field on a silicon chip emitting digitally controlled electron streams under low voltage



NANOX

The Nanox tube

Commercially available
Digital X-Ray source

The Nanox Silicon
MEMs cold cathode

NANOX

The Nanox tube

Significantly smaller
Substantially more cost effective

LEGACY TUBE

$150,000 average cost

NANOX

~$100 estimated cost in mass-production

Enabling a system-level quantum leap

From

Analog
Large and complex
Costs millions of dollars

To

Digital
Small footprint
Costs tens of thousands of dollars

Footprint practicalities



Clinical quality imaging

Nanox | kVp: 50 | mAs: 0.4 |



Philips | kVp: 55 | mAs: 4.0



kVp - Kilovolt Peak. kVp is the component that controls the X-Ray penetration strength and subsequently QUALITY of the X-Ray beam produced. It is also what controls the CONTRAST or GRAY SCALE in the produced X-Ray film. The Higher the kVP the LOWER the CONTRAST.

mAs - MilliAmps per Second. This parameter controls the QUANTITY or the AMOUNT of X-Ray photons produced. This is also what dictates the radiation dose. The higher the mAs the higher the radiation exposure.

NANOX

Clinical quality imaging

3D
Image
Reconstruction





NANOX

The Nanox.ARC 3D computerized tomosynthesis

A new breed of medical imaging systems at a fraction of the cost potentially revolutionizing global availability



Regulatory clearance

FDA

- We expect to take a multi-step approach to the regulatory clearance process:
  - Submitted a 510(K) application in January 2020 relating to a single digital X-ray source version of the Nanox.ARC
  - Received an additional information request in March 2020, which we responded to in September 2020
  - Plan to submit an additional 510(k) application with respect to the multiple-source Nanox.ARC which, if cleared, will be our commercial imaging system
  - We do not believe the Nanox X-ray source (the core component of the Nanox.ARC) will require a separate regulatory approval or clearance because the source is a Class 1 device, which is exempt from the 510(k) application process
- If cleared, we plan to deploy the first Nanox.ARC in the first half of 2021

CE and ROW

- CE submission and clearance expected in H1 2021
- Majority of ROW countries accept FDA and CE as a reference for local clearance
- Other countries will require separate submissions

ADVISORS

Greenleaf Health

Daniel Schultz, MD, F.A.C.S.

Former Director of the Center for Devices and Radiological Health (CDRH) at FDA

NANOX

Our plan

Disrupt the imaging market with a global service infrastructure for medical imaging

- Increase significantly medical imaging availability
- Deploy 15,000 units globally by YE2024 subject to Company financing & regulatory clearance
- Invest CAPEX and own the systems
- Operate a Pay-per-Scan, MSaaS business model
- Generate substantial recurring revenue stream once fully deployed



NANOX

Timeline and key milestones

2012 - 2019

8 years

Development of the Nanox X-Ray Source

Development of the Nanox.ARC

June 2019

Strategic collaboration with FUJI

Strategic collaboration with SK Telecom

2020

January

Secures $20M investment from strategic investors, including Foxconn

Submits 510(k) application of the Nanox.ARC 1

H1

Signs pre-sale agreements for deployment of thousands of units with guaranteed substantial minimum annual service fees for at least 3 years from full deployment

Industrial Alliance, SK Telecom and private investors invest $59M.

FOXCONN

Manufacturing agreement with Foxconn ensures manufacturing quality and consistency

H2

Anticipate signing of additional pre-sale deals globally with minimum annual service fees

2021-2024

from H1 2021

Ramp-up of manufacturing and systems deployments

Expected recurring revenue stream

H1

Anticipated FDA approval of 510(k) submission

First units expected to be manufactured and shipped

2024

Approx. 15,000 units expected to be deployed and operational globally

Addressable market

Expansion of the $21 Billion global medical imaging market through shift from CAPEX to MSaaS model

The X-Ray-based imaging market 2021-2024

Nanox addresses the market segments legacy vendors do not traditionally sell to



Urgent Care units, outpatient clinics, nursing homes etc.

HMOs, hospitals, medical imaging centers

We do not compete over market share, we expand the total market

- We sell medical imaging **availability**
- We expect to provide systems to market segments existing X-Ray vendors don't target
- We target Urgent Care units (over 9,600 in the US alone), outpatient clinics, rural areas, countries with limited medical imaging availability (India, China, Africa…)
- We believe the CAPEX market of HMOs, hospitals and medical centers will migrate to an OPEX service-based model over time
- Nanox is pioneering this model today
- For certain medical imaging market participants, we plan to tailor our X-Ray source technology to their specific imaging systems and we expect to charge a one-time licensing fee upfront and receive recurring royalty payments for each system sold

NANOX

Flexible business model to drive adoption

MSaaS

ILLUSTRATIVE MODEL

POTENTIAL ANNUAL RECURRING REVENUE ASSUMING THE 5,150 CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL



At 20 scans per day, and $14 per scan revenue to NANOX and 23 days per month, the MSaaS model potentially generates over $397 Million in recurring revenues annually

Scans per day - LEGEND

- 7 - Minimum scans per day per system
- 20 - Nanox operational objective
- 60 - Estimated current global average

Pricing model & minimum annual service fee

- Pay-per-scan service business model
- Nanox covers CAPEX investment of systems and deployment
- **$40 total cost per scan as a global average based on current contracts**
- **Nanox revenue $14 (out of the $40) per scan based on current contracts**
- Contracting regional service providers for marketing and operation of the service
- Current contracts provide a minimum annual service fee for 7 scans per day per system against regional exclusivity

- Total number of systems deployed may vary as per financing and final unit cost
- Price-per-scan will vary based on regional economics
- Minimum annual service fees will be backed by a standby letter of credit upon receipt of local regulatory approval

NANOX

Contracted deployments

Current contracts for deals - 5,150 units (Pending local regulatory approval)

- Australia, New Zealand, Norway - 1,000 units
- Taiwan, Singapore - 500 units
- Italy - 500 units
- Spain - 420 units
- Russia - 500 units
- Belarus - 100 units
- South Africa - 500 units
- Brazil - 1,000 units
- Mexico and Guatemala – 630 units



Minimum annual service fees

Nanox current contracts require a minimum annual service fee backed by a standby letter of credit upon receipt of local regulatory approval and satisfaction of all conditions precedent under each agreement

Strategic Collaboration Agreement - 5,500 units

- USA - 3,000 units
- Korea, Vietnam - 2,500 units

- Units of contracted pre-sale deals, with experienced service providers, are expected to be delivered from H1 2021
- Deliveries are conditioned upon acceptance test approval and local regulatory clearance in each region
- Active pipeline of additional countries aiming to join initial wave of deployment

NANOX

Select Customer Profiles

The Gateway Group

- One of Australia's largest independent product distributors including health, wellness, medical supplies and devices
- Provides a wide range of products to over 20,000 locations with representation of medical device companies such as BrainsWay and others
- **Entered into an initial 3-year contract to deploy 1,000 Nanox Systems, consisting of the Nanox.ARC and Nanox.CLOUD, across Australia, New Zealand and Norway[1]**
- **Anticipated $27 million[2] minimum annual service fees to Nanox**

[1] Subject to regulatory approval and customer acceptance test

[2] Assumes 7 scans/day x 23 days/month x at $14 per scan x 1,000 units deployed

NANOX

Select Customer Profiles

SPI Medical, S.A. de C.V. (Mexico)

- SPI Medical, S. A. de C.V. is a distributor of specialty pharma products and medical devices, operating with global leaders such as Abbott, Merck, Bayer and Eli Lilly, and medical imaging systems from Phillips, GE, Siemens, Planmed and Toshiba.
- Distributes to both the public and private sectors in Mexico and Guatemala.
- **Entered into an initial 7-year MSaaS agreement to distribute 630 Nanox Systems across Mexico and Guatemala[1]**
- **Anticipated $17 million[2] minimum annual service fees to Nanox**

SPI MEDICAL, S.A.P.I. DE C.V.

[1] Subject to regulatory approval and customer acceptance test
[2] Assumes 7 scans/day x 23 days/month x at $14 per scan x 630 units deployed

Select Customer Profiles

Promedica Bioelectronics s.r.l. (Italy)

- Promedica Bioelectronics s.r.l. has over 25 years of experience representing diagnostic imaging vendors such as Fujifilm, Siemens Medical Systems and GE Healthcare
- Also manages commercial strategic activities for multinational companies for the marketing of systems with MR-guided Focused Ultrasound (InSightec) and robotic systems for interventional radiology procedures (iSYS)
- **Entered into an initial 4-year MSaaS agreement to distribute 500 Nanox Systems across Italy[1]**
- **Anticipated $13.5 million[2] minimum annual service fees to Nanox**

PROMEDICA BIOELECTRONICS

[1] Subject to regulatory approval and customer acceptance test
[2] Assumes 7 scans/day x 23 days/month x at $14 per scan x 500 units deployed

Select Customer Profiles

APR Tecnologia Salud (Spain and Portugal)

- A distributor of diagnostic imaging equipment across Spain and Portugal
- Offers a full-service integrated approach to its customers comprising both equipment and service
- Expertise across broad range of OEM diagnostic equipment: CT, MRI, Radiology and Ultrasound
- **Entered into a 5-year MSaaS agreement for deployment of 420 Nanox Systems in Spain[1]**
- **Anticipated $11.4 million[2] minimum annual service fees to Nanox**

PRIVATE HEALTHCARE COMPANIES

PUBLIC SECTOR HEALTHCARE

[1] Subject to regulatory approval and customer acceptance test
[2] Assumes 7 scans/day x 23 days/month x at $14 per scan x 420 units deployed

NANOX

USA

Strategic collaboration with USARAD

- Over 250+ U.S. certified radiologists organization
- Providing online, remote radiology services across the U.S.
- 25% owned by Siemens Healthineers

USARAD.com RADIOLOGY-ON-DEMAND® SIEMENS Healthineers



- Working with one strategic partner for nationwide deployments instead of operating a large direct sales force
- Aiming to place 3,000 systems nationwide in the next 2 years
- Urgent care centers, primary care physicians, outpatient imaging centers, chiropractors, veterinarians and more
- Over 9,600 potential locations with unmet needs for medical imaging

Once cleared by the FDA we expect the Nanox.ARC imaging procedures will be covered by radiology CPT reimbursement codes

NANOX

Strategic Alliance with SK Telecom

Collaboration with SK Telecom announced June 2020

- SK Telecom has made two investments in Nanox:
  - $5 million (June 2019)
  - $20 million (June 2020)
- SK Telecom CEO Park Jung-ho joined the Nanox Board of Directors in August 2020



- Collaboration aims to deploy 2,500 Nanox Systems to clinics in South Korea and Vietnam
- Nanox to work toward establishing a wholly-owned subsidiary in Korea to support production of its MEMs X-ray source and leverage SK Telecom's expertise in semiconductors

SK telecom

The Nanox infrastructure management platform

Increasing availability of medical imaging systems solves only half of the problem

Purpose built proprietary radiology software platform streamlines operations and analytics

- Radiology diagnostics remain a significant bottleneck
- All Nanox.ARC systems will be connected to the Nanox.CLOUD
- A proprietary software platform designed to streamline the radiology diagnostics services and provide billing control



The Nanox.CLOUD

A central backbone of our imaging infrastructure that will provide the ability to scale with connectivity to robust services

- Built ground-up with automation, privacy and security in mind
- Expected to be HIPPA and GDPR compliant
- Enables integration into medical systems via APIs
- Full administrative and billing services

NANOX would transmit all imaging data to the cloud SaaS platform

The platform employs a matching engine to match scans to radiologists



Medical AI systems would provide first response and decision assistive information

Radiology specialists would provide diagnostics online

Hospitals and doctors would get real-time global access

Global partnerships

Nanox's cloud-based service will enable medical imaging services globally through its partnerships

Strategic Partners

SK telecom	5G, MEMs manufacturing and APAC distribution
FUJI	Mammography OEM
FOXCONN	Manufacturing

AI Diagnostics

IMEDIS	Cancer detection
Brainomix®	Stroke
qure.ai	Chest & Head
CureMetrix	Mammography

Deployments

USARAD.com RADIOLOGY-ON-DEMAND®	United States
Golden Vine	Taiwan, Singapore
PROMEDICA BIOELECTRONICS	Italy
CLARITY medical solution / ROEL	Russia, Belarus
apf / the Gateway group / SK telecom	Australia, Spain, New Zealand, Norway, Korea Vietnam
LATAM Business Development Group	Brazil, S.Africa
	Mexica, Guatemala



NANOX

The team

A strong execution team with decades of relevant experience and proven track record of large-scale global projects, medical business expertise and bringing innovation to market

Ran Poliakine
Founder & CEO

The founder of the wireless charging industry, a serial entrepreneur focusing on global life-changing technologies and inventions in across multiple categories

Hitoshi Masuya
Co-Founder and Head of NANOX Japan

Originally co-invested in the Nanox project with Sony, now leading the Japan operation and a member of the board

Tal Shank
SVP Corporate Development

Over 15 years of international experience in commercial law and global business development. Tal has a substantial track record with private & public companies

Lydia Edwards
President NANOX USA

Lydia has spent the last 15 years in the medical field, focused on the sales of pulmonary and critical care solutions in the U.S. and international markets

Itzhak Maayan
CFO

Over 25 years of financial leadership roles in multi-national public companies including Perrigo, Cisco Systems, Xtivia Technologies, and Elscint.

Yoel Raab
CTO

Ex-Intel and Orbotech Medical exec., Yoel has BSc. and MSc. degrees in Applied Physics and Microelectronics with a proven track record in product development

Anat Kaphan
VP Product Marketing

Ex Mazor Robotics, Philips Medical, and Lumenis, Anat has an extensive record with over 20 years of experience in medical systems development and marketing

Dr. Amir Ben Shalom
CSO

With over 250 patents granted & pending, Amir is a scientist, engineer, author, teacher and a renown expert in high-power, analog circuits and electro-optics

Bruce Edwards
VP Business Development

A serial entrepreneur in the medical and high-tech fields with an established track record in global marking, sales, and strategic business development

Advisory board


Morry Blumenfeld
GE Healthcare


Prof. Geoffrey D. Rubin
Duke


Prof. Norbert Pelc
Stanford University


Dr. Achille Mileto
University of Washington


Dr. Rafael Grossman
TED


Michael Jackman
GE Healthcare


Dr. Michael Yuz
USARAD


Prof. Peter Dawson
University College London Hospitals NHS


Prof. Yong-woo
Samsung Kangbuk Samsung Hospital


Thomas Deckle
IBM

Professional and involved advisory board of physicians, radiologists, business veterans and global opinion leaders. The Nanox advisory board is an integral part of our think-tank for product roadmap and strategy.

Financial Snapshot

Pro-forma cash*	**Approx. $244 mm**
Debt	**$0**

Expected use of cash	**Amount ($mm)**
Manufacture of 15,000 Nanox.ARC units and investment in manufacturing capacities**	$144 - $194
The shipping, installation and deployment costs of the 15,000 Nanox Systems **	$18 - $30
Continued research and development of the Nanox.ARC, the development of the Nanox.CLOUD and for regulatory clearance in various regions	$5 - $9
The remaining funds, if any, to be used for research and development expenses, sales and marketing expenses, general and administrative expenses and general corporate purposes.	

* Cash and cash equivalents as of June 30, pro-forma for subsequent cross-over funding net proceeds, net IPO proceeds, including full exercise of the 15% underwriters' overallotment option

** To the extent the cost-per-unit of the Nanox.ARC is higher than we expected, we plan to reduce the number of units to be manufactured accordingly.

Key investment highlights

Nanox is a global company building a disruptive medical imaging infrastructure for early detection preventive healthcare



We are well positioned to serve an untapped market representing a significant part of the world's population

- Revolutionary model to transform and grow the already large medical imaging market
- Unique patented technology innovation
- We expect our technology and imaging as a service model will allow us to sell systems into markets and sites that do not have imaging systems and where our traditional imaging competitors cannot play
- Transformative business model disrupts by no longer focusing on high cost capital equipment, but instead, into a recurring revenue service model with software-like gross margins
- Business model allows company to focus on a handful of key deployment partners like radiology groups in the US vs thousands of hospitals and imaging centers, with a small focused clinical support team
- Anticipated 510(k) regulatory path for the Nanox.ARC in US and well-known ROW regulatory paths
- No reimbursement hurdles expected and stable codes familiar to all physicians
- Significant positive economic impact on radiology groups and individual practices

- **Nanox has a first mover advantage**
- **Developed a novel digital X-Ray source**
- **Global strategic partnerships with industry leaders**
- **Exceptional execution team**
- **A strong business model with contracts for 5,150 units that include a minimum annual service fee backed by a standby letter of credit upon receipt of regulatory approval**



NANOX

Thank you

NANOX

Presenters

Lydia Edwards
President Nanox USA

Ran Poliakine
Founder & CEO

Itzhak Maayan
CFO

IU Kim
President SK Telecom
HK Office